<span item_type="fundamental" item_id="b14a03b802e9a46beff1065f35a96d8c" counter_id="ST/US/CINGW" env="prod"></span><span item_type="announcement" item_id="513936802707671425" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -1.04.</p><p>EBIT: As of FY2025 Q1, the actual value is USD -3.803 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Clinical Operations</strong>: $1,107,474 for the three months ended March 31, 2025, compared to $1,077,190 for the same period in 2024, representing a 2.9% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li><li><strong>Drug Manufacturing and Formulation</strong>: $380,353 for the three months ended March 31, 2025, compared to $341,199 for the same period in 2024, representing an 11.4% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: $3,802,691 for the three months ended March 31, 2025, compared to $2,972,477 for the same period in 2024, representing a 28.0% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li><li><strong>Operating Loss</strong>: $3,706,035 for the three months ended March 31, 2025, compared to $2,948,217 for the same period in 2024, representing a 25.7% increase.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $4,608,282 for the three months ended March 31, 2025, compared to - $8,746,360 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $1,915,927 for the three months ended March 31, 2025, compared to $9,889,283 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Stock-Based Compensation Expense</strong>: $357,649 for the three months ended March 31, 2025, compared to $164,575 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to file its NDA submission for CTx-1301 in mid-2025 and believes its cash will satisfy capital needs into the fourth quarter of 2025 under the current business plan.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company received a grant of $3 million to support the clinical and manufacturing development of CTx-2103, with payments contingent on specific milestones.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li></ul><h3>Priority</h3><ul><li>The company is actively seeking strategic partnerships for licensing CTx-1301 in the United States and internationally, and has entered into a master services agreement with Indegene for commercialization services.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1862150/000164117225009289/form10-q.htm"></span></li></ul>

CINGULATE INC C/WTS 10/12/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -1.04